The company’s preliminary results reveal a complex landscape of regional performance. While Staar reported robust momentum in China and double-digit growth across the Americas, the EMEA region faced a low-single-digit decline. Management attributed this weakness primarily to ongoing turmoil in the Middle East, noting that excluding those specific markets, the broader EMEA region actually posted double-digit gains.
In section Market Quotes
Staar Surgical Shares Dip on Narrow Revenue Miss
Investors pushed Staar Surgical stock down 12% in after-hours trading Thursday, wiping out earlier gains after the company projected second-quarter sales of $90 million. The figure sits just below the $90.2 million consensus estimate from Wall Street analysts, signaling a rare moment of hesitation for the high-growth medical device firm.
Despite the immediate market reaction, the company remains up 26% year-to-date. Leadership cautioned that geopolitical and macroeconomic volatility remains a lingering risk, warning that broader instability could further impact future results. Staar Surgical is scheduled to provide a comprehensive breakdown of its quarterly performance on August 12.
Comments (0)
No comments yet. Be the first!